Related Experiment Video

Updated: Jun 7, 2026

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

20.3K

Immunoadsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders - A retrospective

Paula Cramer1, Marc Nikolaus2, Sebastian Loos3

  • 1Department of Paediatric Nephrology, Gastroenterology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.

European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
|January 3, 2025
PubMed

Insights

Therapeutic apheresis, including immunoadsorption (IA) and plasma exchange (PE), shows promise for treating pediatric neuroimmunological disorders. Both methods demonstrated comparable effectiveness and safety in improving neurological outcomes in children and adolescents.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Therapeutic apheresis (TA) offers a promising treatment for neuroimmunological disorders.
  • Limited data exists on TA, specifically immunoadsorption (IA), in pediatric populations.
  • This study analyzes the use of plasma exchange (PE) and IA in children and adolescents.

Purpose of the Study:

  • To analyze the utilization of PE and IA in pediatric neuroimmunological disorders.
  • To evaluate the treatment outcomes and neurological course following TA.
  • To assess the safety profile of PE and IA in pediatric patients.

Main Methods:

  • Retrospective analysis of clinical data from pediatric patients treated with TA.
  • Data collected from two German university children's hospitals between 2015 and 2022.
  • Inclusion criteria: pediatric patients with neuroimmunological disorders undergoing TA.

Main Results:

  • 39 patients underwent 322 TA sessions (184 IA, 138 PE).
  • Autoimmune encephalitis was the most common diagnosis (39%).
  • Overall improvement observed in 76% immediately post-treatment and 88% one month later, with no significant difference between IA and PE.
  • Complication rate was 13% for both IA and PE, mostly moderate.

Conclusions:

  • Both IA and PE are effective therapeutic options for pediatric neuroimmunological disorders.
  • No significant differences in efficacy or safety were found between IA and PE.
  • TA is a viable treatment modality for improving neurological function in children and adolescents with these conditions.
Abstract

Keywords:
Autoimmune encephalitisImmunoadsorption (IA)Neuroimmunological disordersPlasma exchange (PE)

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...